AbbVie ABBV Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Product | ||||||
| All other | $2.91B-18.0% | $3.13B+3.3% | $3.27B+5.4% | $3.33B+5.6% | $3.54B+14.7% | |
| Botox Cosmetic | $2.71B+2.7% | $2.6B-4.3% | $2.57B-6.5% | $2.61B-3.5% | $2.64B-0.5% | |
| Botox Therapeutic | $3.91B+15.0% | $3.77B+14.8% | $3.65B+14.6% | $3.52B+13.9% | $3.4B+12.6% | |
| Elahere | $709M+19.4% | $690M+44.1% | $656M+98.2% | $625M+226% | $594M+828% | |
| Epkinly | $303M+78.2% | $271M+85.6% | $230M+87.0% | $204M+117% | $170M+193% | |
| Humira | $4.11B-47.6% | $4.54B-49.5% | $4.98B-53.1% | $6.21B-48.0% | $7.84B-40.3% | |
| Imbruvica | $2.69B-17.2% | $2.87B-14.3% | $3.05B-10.5% | $3.17B-9.0% | $3.25B-8.7% | |
| Juvederm Collection | $994M-10.5% | $993M-15.6% | $1.02B-17.0% | $1.03B-20.6% | $1.11B-15.8% | |
| Linzess | $1.04B+24.6% | $907M-4.9% | $965M-3.9% | $873M-17.5% | $836M-25.0% | |
| Mavyret | $1.36B+7.4% | $1.32B+0.5% | $1.28B-3.4% | $1.27B-8.8% | $1.27B-10.4% | |
| Other Aesthetics | $1.24B-3.1% | $1.27B-1.1% | $1.28B+0.9% | $1.28B+2.4% | $1.28B+0.6% | |
| Other Neuroscience | $273M-17.0% | $303M+26.8% | $312M+26.8% | $322M+28.3% | $329M+27.0% | |
| Qulipta | $1.14B+58.2% | $1.04B+57.4% | $949M+66.2% | $837M+58.8% | $720M+52.2% | |
| Rinvoq | $8.71B+32.0% | $8.3B+39.1% | $7.76B+44.0% | $7.19B+47.2% | $6.6B+50.7% | |
| Skyrizi | $18.62B+41.8% | $17.56B+49.9% | $16.33B+58.1% | $14.83B+60.2% | $13.14B+56.2% | |
| Ubrelvy | $1.37B+31.4% | $1.27B+26.3% | $1.24B+31.8% | $1.15B+27.6% | $1.04B+20.4% | |
| Venclexta | $2.9B+10.0% | $2.79B+8.1% | $2.74B+8.7% | $2.69B+10.6% | $2.63B+11.4% | |
| Vraylar | $3.76B+12.7% | $3.62B+10.8% | $3.52B+12.5% | $3.46B+15.2% | $3.34B+15.4% | |
| Vyalev | $620M+305% | $482M+387% | $343M+515% | $233M+718% | $153M+1,260% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does AbbVie break its business down?
- AbbVie (ABBV) reports net revenues by product across 19 parts — All other, Botox Cosmetic, Botox Therapeutic, Elahere and Epkinly. Each is extracted from the segment footnotes and tracked over time.
- Where does AbbVie's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AbbVie's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
